Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Leti and Akrivis Develop Nanomedicine Platform for High Payload Targeted Drug Delivery

Published: Saturday, June 21, 2014
Last Updated: Friday, June 20, 2014
Bookmark and Share
New theranostic platform will combine ultrasensitive detection, high payloads and more efficient cell targeting.

CEA-Leti and Akrivis Technologies, LLC have announced their collaboration to develop an extremely adaptable, efficient and highly targeted drug delivery platform for chemotherapy and other treatments that require a high concentration of powerful drugs to be delivered precisely to targeted cells.

The new platform will be based on Akrivis Technologies’ proprietary Z–TECT™ technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot® nanovector delivery capability.

Developed by Akrivis Technologies, LLC, a biopharmaceutical company based in Cambridge, Mass. USA, Z–TECT™ is a unique technology platform that combines nanotechnology, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection in vitro and imaging in vivo.

Developed by Leti and introduced for commercial uses in 2011, the Lipidot® technology is a versatile nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.

By combining their delivery and targeting platforms, Leti and Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells. The resulting targeted nanoparticles will be optimized in a first phase for research and pre-clinical in vitro and in vivo applications. Then, in a second phase, they will be further developed clinically for in vitro diagnostics, in vivo imaging and targeted therapy.

“The new targeted nanoparticles jointly developed by Leti and Akrivis Technologies will dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects,” said Patrick Boisseau, head of Leti’s nanomedicine program and chairman of the European Technology Platform – Nanomedicine (ETPN). “While specifically designed to meet the needs of pharmaceutical and biotech companies, the new platform will be customizable for other end-user applications such as diagnostics and theranostics.”

“Detecting disease earlier and delivering the precise drug dosage at the right place at the right moment are major steps towards improving patient diagnosis and treatment as well as controlling healthcare costs,” said Joel Berniac, CEO of Akrivis Technologies. “Akrivis and Leti have highly complementary nanomed technology platforms that will come together and offer physicians powerful new options for diagnosis and treatment.”

Supported by AEPI, the Grenoble-Isère economic development agency, Akrivis Technologies and Leti created a joint lab, which was launched on June 2.

“Leti’s collaboration with Akrivis Technologies underscores Grenoble’s strengths as a center for nanomedicine R&D and we are very pleased that they chose Leti and Grenoble for this exciting research and development project,” said Joëlle Seux, AEPI director.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leti and Diabeloop Project Aims at Developing Artificial Pancreas
Artificial pancreas will automatically deliver the appropriate dose of insulin to patients.
Saturday, July 25, 2015
Leti Announces Launch of First European Nanomedicine Characterization Laboratory
Project combines expertise of 9 partners in 8 countries to foster nanomedicine innovation and facilitate regulatory approval.
Tuesday, July 07, 2015
Eveon, Leti Mark Milestone in Fabrication of Smart Bolus-type Micro-pump
Both Companies announces the demonstration of liquid-pumping for smart drug delivery.
Friday, March 14, 2014
Leti Announces Project to Develop New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Tuesday, February 18, 2014
PIEZOMAT Project Targets New Fingerprint Technology
Ultra-high resolution sensing uses vertical piezoelectric nanowire matrices to reconstruct the smallest features of human fingerprints.
Thursday, February 13, 2014
Leti Announces MEMS Research Collaboration with OMRON
Leti’s first collaboration with a Japanese MEMS producer.
Monday, December 09, 2013
CEA-Leti Signs Agreement with Qualcomm
Agreement to assess Leti’s sequential 3D technology.
Monday, December 09, 2013
Alim-Louis Benabid Honored by U.S. Research Institute
Benabid has received the Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research.
Friday, October 11, 2013
CEA-Leti Announces €1 Million Funding
bpifrance (ex OSEO) awarded grant to speed preclinical development of cancer-detecting nanoparticles.
Thursday, July 04, 2013
Patrick Boisseau Elected Chairman of the ETPN
Program will focus on building a structure that speeds innovations’ time to market and patients, while keeping Europe’s nanomed IP at home.
Monday, March 25, 2013
Attolight and Leti Launch Joint-Development Program
Program to extend applications for Company’s cathodoluminescence technology.
Monday, October 29, 2012
CEA-Leti and 7 Partners to Study Ways to Improve Treatment of Inflammatory Bowel Disease
Goal is to develop nanocarrier for targeted delivery of corticosteroids and immunosuppressants.
Thursday, April 14, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos